Last Updated: 30 Jul 2025
Source: Statifacts
Genetic Materials Market (By Product & Service: Poultry, Swine, Cattle, Other Live Animals; By Type: DNA, RNA, Genes, Chromosomes; By Application: Genomics, Drug Discovery, Proteomics, Bioinformatics, Synthetic Biology, Others; By End User: Pharmaceuticals, Medicines, Agriculture, Others; By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa) Industry Size, Share, Growth, Trends 2026 to 2035.
The global genetic materials market size was evaluated at USD 3.01 billion in 2025 and is expected to grow around USD 6.31 billion by 2035, growing at a CAGR of 7.68% from 2025 to 2034.
| Reports Attributes | Statistics |
| Market Size in 2025 | USD 3.01 Billion |
| Market Size in 2026 | USD 3.24 Billion |
| Market Size in 2032 | USD 5.09 Billion |
| Market Size by 2035 | USD 6.31 Billion |
| CAGR 2026 to 2035 | 7.68% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
The genetic materials market is undergoing remarkable growth across numerous segments, including gene therapy, genetic engineering, and genetic testing. The market is driven by factors such as increasing need for biopharmaceuticals, developments in gene editing technologies, and the increasing knowledge of genetic diseases.
The market's expansion is closely tied to developments in proteomics, genomics, and molecular biology, driving progress in areas such as diagnostics, gene editing, and personalized medicine. The huge amount of genetic information generated by genomics research needs advanced data analysis techniques as well as AI to unlock its full potency for discernment of complex genetic patterns, forecasting disease risks, and advancing new therapies.
AI is transforming the genetic materials market by speeding up research, enhancing accuracy, and permitting personalized medicine. AI algorithms can determine vast genomic datasets, identify disease-associated genetic variations, and forecast treatment responses, contributing to more effective as well as tailored therapies. AI algorithms can decrease errors in DNA sequencing and analysis, resulting in more accurate results. AI can also streamline the drug discovery process by determining potential drug targets and forecasting drug efficacy. This includes improving gene therapy approaches and predicting the results of gene editing techniques such as CRISPR-Cas9.
AI algorithms can remarkably shorten the time and cost linked with genome sequencing. They can process and determine massive genomic datasets to recognize genetic variations, including those associated with diseases. While AI provides numerous benefits, ethical considerations linked to data privacy as well as security must be addressed. Ensuring responsible data handling along with algorithmic transparency is vital for maintaining public trust and encouraging the ethical use of AI in genetics.
For instance, AI can aid in identifying which gene changes cause cancer, thus speeding up early detection and personalized treatments. It can also accelerate the discovery of new drugs by determining genetic data to find possible targets.
Raising awareness about genetic testing is a significant driver for the genetic material market because increased awareness and understanding of genetic testing advantages lead to a greater need for related services and products. Greater knowledge of the potential of genetic testing to determine predispositions to diseases (such as heart disease, cancer, or inherited disorders) stimulates individuals to seek testing earlier, certainly before symptoms appear. Awareness enables individuals to take a more dynamic role in handling their health by understanding their genetic risks along with taking appropriate preventative measures. As awareness expands, there is a drive to make genetic testing more affordable and accessible, thus driving market growth.
Intellectual property (IP) complexities, specifically those surrounding patents and trade secrets, can significantly restrain the genetic material market by creating barriers to entry and hampering innovation. Securing patents, especially internationally, involves remarkable legal and administrative fees, making it expensive for smaller firms as well as research institutions to protect their innovations.
The legal landscape surrounding genetic inventions is constantly evolving, contributing to uncertainty around what is patentable and what is not, potency discouraging investment in certain areas of research.
Advancements in gene editing technologies, particularly CRISPR-Cas9, are creating significant opportunities for the genetic materials market by permitting more precise as well as efficient modifications of DNA, contributing to new possibilities in agriculture, healthcare, and other fields. Gene editing is being examined for treating a broad range of diseases, including genetic disorders, infectious diseases, and cancers. This includes the advancement of personalized medicine approaches that need specific genetic material for each patient.
"As a Swiss-based company with a significant presence in the US, these investments will enable us to fully bring our supply chain and key technology platforms into the US to support our strong US growth outlook. These investments also reflect the pro-innovation policy and regulatory environment in the US that supports our ability to find the next medical breakthroughs for patients," said Vas Narasimhan, CEO of Novartis. "We are prepared for shifts in the external environment and fully confident in our 2025 guidance, mid- to long-term sales growth outlook, and 2027 core margin guidance of 40%+."
“We’re excited to partner with BioDot to deliver a turnkey hematology FISH solution, combining the precision of Empire Genomics’ probes with an automation platform designed to conserve valuable reagents,” said John Steel, Senior Vice President of Empire Genomics. “Our collaboration with BioDot ensures that labs can now trust not just in the quality of their instrumentation, but in the probe chemistry itself reducing time-to-clinical data and improving consistency across laboratories.”
“We have an exciting, diverse, and sizable slate of oncology results being presented at ASCO this year, where each demonstrates our ongoing commitment to advancing clinical care,” said Dale Muzzey, PhD, chief scientific officer, Myriad Genetics. “The research efforts we’re undertaking with leading organizations and investigators are an important step in advancing the clinical application of our oncology products and personalized care for all patients. Particularly, we’re excited to share the latest results from two MRD studies with collaborators at the National Cancer Center Hospital East, Japan, and Memorial Sloan Kettering (MSK), which demonstrate the exceptional performance we’re seeing from our ultrasensitive assay, Precise® MRD.”
The poultry segment dominated the genetic materials market in 2024. Poultry genetics is important for maximizing yield, driving disease resistance, as well as efficiently meeting the worldwide need for poultry meat and eggs. Genetic advancements in poultry aim to enhance efficiency, welfare, and health, while also tackling environmental impact and sustainability concerns.
The cattle segment is the fastest-growing in the genetic materials market during the forecast period. This is mainly due to the growing global requirement for dairy and meat products, which boosts the demand for genetically superior cattle. The usage of technologies such as artificial insemination, genomic selection, and embryo transfer permits more efficient and precise breeding of cattle, contributing to rapid genetic improvement. There's an increasing emphasis on sustainable dairy as well as meat production, which thus encourages the acceptance of precision breeding strategies in cattle.
The DNA segment dominated the genetic materials market in 2024. This supremacy is due to DNA's fundamental part in genetic research and diagnostics, along with drug development, especially in areas such as gene therapy and personalized medicine. The market is boosted by ongoing developments in genomics, genetic engineering, and the increasing field of synthetic biology, which heavily depends on DNA. DNA applications span gene therapy, genetic testing, personalized medicine, as well as drug discovery.
The RNA segment is the fastest-growing in the genetic materials market during the forecast period. This growth is boosted by rising research and development in RNA-based therapies, developments in RNA sequencing technologies, and the rising acceptance of RNA sequencing in clinical diagnostics as well as personalized medicine. The advancement and application of RNA-derived therapies, including mRNA vaccines as well as other RNA therapeutics, have seen remarkable growth, mainly in response to the COVID-19 pandemic. A surge in research activities aimed at RNA's role in gene expression, disease mechanisms, along therapeutic development is driving the need for RNA-related products and services.
The genomics segment dominated the genetic materials market in 2024. This is largely driven by developments in genetic sequencing technologies and the rising demand for personalized medicine. This area is mainly significant, targeting the functions of genes and their interactions within a cell or organism. Genomics is used in various areas, including diagnostics, drug discovery and development, precision medicine, and agricultural research.
The drug discovery segment shows notable growth in the genetic materials market during the forecast period. Genomics, the application of an organism's entire genome, offers insights into the genetic basis of diseases. This knowledge is vital for determining disease-causing genes and pathways, which can be targeted by drugs. By analyzing an individual's genetic makeup, pharmacogenomics can aid in tailoring drug treatments to reduce effectiveness and minimize adverse effects. AI and machine learning are playing an increasingly vital role in drug discovery by analyzing massive datasets of genetic data, chemical compounds, along clinical trial data. These technologies can assist in predicting drug efficacy and safety, determining potential drug candidates, and improving drug development pipelines.
The pharmaceutical segment dominated and is expected to sustain the position with the fastest rate of growth in the genetic materials market in 2024. The growth of personalized medicine, which tailors treatments to individual genetic profiles, depends heavily on genetic materials such as DNA and RNA. The pharmaceutical industry is heavily involved in developing gene therapies, which require introducing genetic material into cells to treat or prevent disease. This is a rapidly increasing area with remarkable pharmaceutical investment. The pharmaceutical industry also boosts the drug discovery services market, mainly the hit-to-lead identification segment, which is vital for identifying promising drug candidates.
North America dominated the genetic materials market in 2024. This is because of the region's well-known biotechnology and pharmaceutical industry, developed healthcare infrastructure, as well as strong investment in gene therapy research. The existence of leading market players with remarkable operations in the United States and Canada, along with solid academic and research institutions, thus strengthens North America's position.
The competitive landscape of the genetic materials market is featured by a mix of well-known players and emerging firms, with significant growth boosted by developments in genetic testing, personalized medicine, and new technologies. The market includes companies targeting numerous aspects of genetic materials, such as gene therapy, animal genetics, and genetic testing, each with its own set of major players and competitive dynamics.
Illumina Inc. offers genomic sequencing as well as array-derived solutions for genetic determination in the areas of molecular diagnostics, cancer, and translational and consumer genomics. It also provides services such as whole-genome sequencing, NIPT, microarray services, genotyping, instrument services, consulting, training, and product support services.
Agilent differentiates itself via product performance, reliability, strong application expertise, as well as global channel coverage. It highlights its strong global presence and capability to offer support to its customers worldwide.
QIAGEN participates with companies of numerous sizes, from large, diversified corporations such as Danaher to smaller, specialized firms such as Biofidelity. It functions worldwide, and its competitive landscape includes regional players in different markets.
| Regions | Shares (%) |
| North America | 21.77% |
| Asia Pacific | 31.22% |
| Europe | 25.11% |
| LAMEA | 21.9% |
| Segments | Shares (%) |
| Poultry | 25.98% |
| Swine | 24.15% |
| Cattle | 28.09% |
| Other Live Animals | 21.78% |
| Segments | Shares (%) |
| DNA | 23.09% |
| RNA | 24.92% |
| Genes | 26.85% |
| Chromosomes | 25.14% |
| Segments | Shares (%) |
| Genomics | 18.34% |
| Drug Discovery | 15.85% |
| Proteomics | 19.12% |
| Bioinformatics | 16.91% |
| Synthetic Biology | 17.42% |
| Others | 12.36% |
| Segments | Shares (%) |
| Pharmaceuticals | 27.48% |
| Medicines | 21.11% |
| Agriculture | 23.92% |
| Others | 27.49% |
Published by Rohan Patil
